

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT7292705

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
PATRICIUS HENDRIKUS CORNELIS VAN BERKEL	05/22/2018
RECEIVING PARTY DATA	
Name:	ADC THERAPEUTICS (UK) LIMITED
Street Address:	GEORGE STREET
Internal Address:	4TH FLOOR READING BRIDGE HOUSE
City:	READING, BERKSHIRE
State/Country:	UNITED KINGDOM
Postal Code:	RG1 8LS
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	17484467
CORRESPONDENCE DATA	
Fax Number:	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	6086621277
Email:	resivigny@casimirjones.com
Correspondent Name:	CASIMIR JONES
Address Line 1:	2275 DEMING WAY
Address Line 2:	SUITE 310
Address Line 4:	MIDDLETON, WISCONSIN 53562
ATTORNEY DOCKET NUMBER:	MEWB-37864.402
NAME OF SUBMITTER:	LISA MUELLER
SIGNATURE:	/Lisa Mueller, Reg. No. 38978/
DATE SIGNED:	04/22/2022
Total Attachments: 4	
source=2022-04-21-37864-402_Assignment-Exec#page1.tif	
source=2022-04-21-37864-402_Assignment-Exec#page2.tif	
source=2022-04-21-37864-402_Assignment-Exec#page3.tif	
source=2022-04-21-37864-402_Assignment-Exec#page4.tif	

ASSIGNMENT OF INVENTION & PATENT RIGHTS

Parties

Cornelis PVB 11 sep 2019

- (1) VAN BERKEL, PATRICIUS HENDRIKUS CORNELIUS c/o ADC Therapeutics SA, Route de la Corniche 3b, 1066 Epalinges, Switzerland (the "Inventor");
- (2) ADC THERAPEUTICS (UK) LIMITED incorporated and registered in England & Wales with company number 09353055 whose registered office is at 4th Floor Reading Bridge House, George Street, Reading, Berkshire, RG1 8LS (the "Employer");
- (3) ADC THERAPEUTICS SA incorporated and registered in the Swiss Confederation and whose principal office is at Route de la Corniche 3b, 1066 Epalinges, Switzerland ("ADCT"); and
- (4) MEDIMMUNE LIMITED incorporated and registered in England & Wales with company number 02451177 whose registered office is at Millstein Building, Granta Park, Cambridge, CB21 6GH ("MedImmune")

Agreed terms

1. Definitions

The definitions in this clause apply in this Assignment.

"Completion Application" means the completion patent application, short particulars of which are set out in Part 2 of the Schedule.

"Invention" means the invention entitled PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES, being the subject matter of the Priority Applications.

"Patent Applications" means the Priority Applications, the Completion Application and any future applications linked by one or more priorities to the Priority Applications or the Completion Application and all matter contained in such applications and any and all:

- (a) national and regional phase applications of all such applications; and
- (b) divisions, continuations and continuations-in-part of all such applications; and
- (c) patents that may be granted pursuant to any of the aforesaid applications for their full period, including any re-issues, re-examinations, renewals, extensions and Supplementary Protection Certificates.

"Priority Applications" means the priority patent applications, short particulars of which are set out in Part 1 of the Schedule.

2. Assignment

In consideration of the sum of £1 (sufficiency and receipt of which the Inventor, the Employer and ADCT expressly acknowledge), the Inventor hereby assigns absolutely to the Employer, thereafter the Employer hereby assigns absolutely to ADCT, and thereafter ADCT hereby assigns absolutely to MedImmune a one half share in all its right, title and interest in

all countries, regions and territories of the world in, to and arising from the invention and, with effect from immediately prior to the filing of each, the Patent Applications, to the effect that any and all patents granted therefrom shall vest jointly in equal and undivided share and proceed jointly in the names of ADCT and MedImmune, including (but not limited to):

- (a) in respect of the invention and any invention that shall be disclosed in, and all matter that shall be contained in, any of the Patent Applications, the right to file applications, claim priority from such applications, and prosecute and obtain grant of patent or other intellectual property protection in respect of any country, region or territory in the world;
- (b) in respect of each and any Patent Application:
 - (i) the right to claim priority from and to prosecute and obtain grant of patents; and
 - (ii) the right to file divisional applications based on the Patent Applications and to prosecute and obtain grant of patent on each and any such divisional application;
- (c) the right to extend to, or register in or in respect of any country, region or territory in the world, each and any of the Patent Applications and to extend to or register in, or in respect of, any country, region or territory in the world any patent or other intellectual property protection granted on any of such applications;
- (d) the absolute entitlement to any patents granted pursuant to any Patent Application; and
- (e) the right to bring, make, oppose or defend claims or actions, appeal proceedings and obtain relief (and to retain any damages recovered) in respect of any infringement, or any other cause of action arising from ownership, of the inventions and the Patent Applications, whether occurring before on or after the date of this Assignment.

3. **Further assurance**

The inventor, the Employer and ADCT shall, at ADCT's and MedImmune's joint cost, perform all further acts and things, and execute all further documents, required by law or which ADCT and MedImmune request to vest jointly in ADCT and MedImmune the full benefit of the right, title and interest assigned to ADCT and MedImmune under this Assignment, including (but not limited to):

- (a) documents required to be signed by or on behalf of the inventor, the Employer or ADCT in the course of any applications which relate to the invention or to any inventions that shall be disclosed in any of the Patent Applications;
- (b) registration of ADCT and MedImmune as co-applicant for, or co-proprietor of, the Patent Applications; and
- (c) assisting ADCT and MedImmune in obtaining, defending and enforcing any of the Patent Applications; and assisting with any other proceedings which may be brought by or against ADCT and/or MedImmune by any third party or in the resolution of any question concerning the invention, or the Patent Applications or any inventions that shall be disclosed in any of the Patent Applications.

4. **Right to amend the Schedule**

The Inventor, the Employer, ADCT and Medimmune grant the firm of Mewburn Ellis LLP the right to insert in Part 3 of the Schedule to this Assignment any further identification of any existing or future patent applications in any countries, regions or territories of the world, which shall fall within the scope of clause 2 above, or as may be necessary or desirable in order to comply with the rules of a patent office for the recordal of this Assignment.

5. **Counterparts**

This Assignment may be executed in any number of counterparts, each of which when executed shall constitute an original of this Assignment, but all the counterparts shall together constitute the same agreement.

6. **Governing law and jurisdiction**

This Assignment is governed by the laws of England and Wales and subject to the exclusive jurisdiction of its courts.

Schedule: The Patent Applications

Part 1: Priority Applications

Country	Application No.	Application Date	Title
GB	1702029.8	08 February 2017	PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES
GB	1702031.4	08 February 2017	PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES
GB	1719906.8	30 November 2017	PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES

Part 2: Completion Application

Country/region	Application No.	Application Date	Title
WO	PCT/EP2018/053163	08 February 2018	PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES

Part 3: Identification of some, but not necessarily all, patent applications falling within the scope of clause 2 of this Assignment

Country/region	Application No.	Application Date	Title	Signature for Mewburn Ellis LLP

CORNELIUS
PvB
11-SEP-2018

Executed by PATRICIUS HENDRIKUS
CORNELIUS VAN BERKEL in the presence
of:


SIGNATURE OF INVENTOR


SIGNATURE OF WITNESS

NAME: LISA SKELTON
ADDRESS: 4 HAREFIELD ROAD, RICHMOND, W3 1LU
OCCUPATION: HEAD OF PROJECT MANAGEMENT
DATE: 22 MAY 2018

Executed by ADC THERAPEUTICS (UK)
LIMITED acting by NA. FORSTER, a
director, in the presence of:


SIGNATURE OF A DIRECTOR


SIGNATURE OF WITNESS

NAME: CHRISTINE WAITE
ADDRESS: CH. PREC-LEC BOIS 56, 1066 EPALINGES, SWITZERLAND
OCCUPATION: OFFICE & ADMINISTRATION MANAGER
DATE: MAY 25, 2018

Executed by ADC THERAPEUTICS SA acting
by C. MARTIN, a director, in the
presence of:


SIGNATURE OF A DIRECTOR


SIGNATURE OF WITNESS

NAME: CHRISTINE WAITE
ADDRESS: CH. PREC-LEC BOIS 56, 1066 EPALINGES SWITZERLAND
OCCUPATION: OFFICE & ADMINISTRATION MANAGER
DATE: MAY 25, 2018

Executed by MEDIMMUNE LIMITED acting
by Christopher Winter, an authorised
signatory, in the presence of:


SIGNATURE OF C S WINTER


SIGNATURE OF WITNESS

NAME: B. INCE
ADDRESS: 2 RIVERSIDE, MILSTEIN BUILDING, SKANTA PARK, CAMBS CB21 6QH
OCCUPATION: PERSONAL ASSISTANT
DATE: 8 AUG 2018